Response to the Letter to the Editor concerning ‘Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’-Reference-Cited by-同舟云学术

Response to the Letter to the Editor concerning ‘Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’

Published:2024-08 Issue:1 Volume:38 Page:
ISSN:1310-2818
Container-title:Biotechnology & Biotechnological Equipment
language:en
Short-container-title:Biotechnology & Biotechnological Equipment

Author:

Stević Ivana¹,Janković Slobodan M.²

Affiliation:

1. Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

2. Pharmacology Department, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13102818.2024.2386488

Reference5 articles.

1. Stevenson AL Chang-Douglass S Kazmierska P et al. Letter to the Editor concerning ‘Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’.

2. Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis

3. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis

4. Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis

5. National Institute for Health and Care Excellence (NICE). Velmanase alfa for treating alpha- mannosidosis. NICE Technology Appraisal Guidance HST29; 2023. [cited 2024 Jun 28]. Available from: https://www.nice.org.uk/guidance/hst29